XJPX
4599
Market cap63mUSD
Oct 09, Last price
164.00JPY
1D
2.50%
1Q
-48.10%
IPO
-83.35%
Name
StemRIM Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.46%
Rev. gr., 5y
63.68%
Revenues
0
Net income
-1.85b
L-4.04%
CFO
-1.61b
L+13.81%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoing Phase II clinical trials for a range of conditions such as epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy. Beyond PJ1, StemRIM is also advancing PJ2, another regeneration-inducing medicine utilizing novel peptides A and B; PJ3, a biologic protein designed to promote regeneration; PJ4, a device for collecting a patient's own cells for therapeutic purposes; and PJ5, a stem cell-based gene therapy. Established in 2006, StemRIM is headquartered in Ibaraki, Japan.
Key people
Masatsune Okajima
President, Chief Executive Officer, Representative Director · since 2023
Takehiko Yamazaki
Executive Officer, Director of Intellectual Property · since 2022
Katsuto Tamai
CSO, Director · since 2022
Kensuke Tomita
Chairman of the Board · since 2023
Tadahiro Nagai
Independent Director · since 2020
Noriko Sawai
Independent Director · since 2019
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑07 | 2025‑07 | 2024‑07 | 2023‑07 | 2022‑07 | 2021‑07 | 2020‑07 | 2019‑07 | 2018‑07 | 2017‑07 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||